Customer
![subVisual](/default/img/pure/sub_img5.jpg)
Name | Manager |
Subject | AGF39 efficacy history, how AGF39 could be the standard mesotherapy solution for alopecia? |
Date | 2023-03-22 |
Q. AGF39 efficacy history, how AGF39 could be the standard mesotherapy solution for alopecia?
AGF39 started 3 growth factors of IGF-1, VEGF, and bFGF in 2008 as the name of SGF-57. We underwent many trials and errors. We recalled our product 4 times 2011, 2013, 2014, and 2018. And gradually upgraded our prescriptions and manufacture processes. In 2011, we progressed a clinical study to confirm basic dose of cytokine vial with our new prescription at the medical center of catholic university. Fortunately, the article published on Journal of Dermatology in 2012, one of SCI level. We defined the most rational cytokine number is 7 and first prescribed IGF-1, VEGF, bFGF, KGF, Noggin, SCF and SOD. Then set up the theory of Cytokines therapy for alopecia treatment. In 2012 and 2013 we progressed more clinical study to confirm the program of procedure and new ingredient of FGF9 at Myong Ji hospital of Kwandong university. Our Cytokines therapy for alopecia was first announced at the place of WCHR 2013 in Edinburg and WCHR2014 in Jeju island on those clinical studies of Myong Ji hospital. In 2016, we launched a new brand of AGF39 which includes FGF9, a cytokine of WNT promotor. In 2018, we first attended KIMES to meet overseas clients. Now we have 500 clinic clients from the top in alopecia department in domestic, and overseas partners from 8 countries including China, Japan, Malaysia, and Turkiye. |